11 Results for "

FLT3-ITD-positive

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "FLT3-ITD-positive" in MCE Product Catalog:

Cat. No.: HY-172581
CAS No.: 1862226-99-0
Research Areas:  

Cancer

Clifutinib is an orally active and selective internal tandem duplication mutation of FMS-like tyrosine kinase 3 (FLT3-ITD) inhibitor with an IC50 value of 15.1 nM. Clifutinib exerts strong antiproliferative effects on FLT3-ITD acute myeloid leukemia (AML) cell lines (MV-4-11: IC50 = 1.5 nM; MOLM-13: IC50 = 1.4 nM). Clifutinib inhibits the activity of FLT3-ITD kinase and blocks the downstream RAS/MAPK, PI3K/AKT, and JAK/STAT5 signaling pathways of FLT3. Clifutinib induces apoptosis of acute myeloid leukemia (AML) cells with FLT3-ITD mutations. Clifutinib demonstrates significant antitumor efficacy in mice bearing MV-4-11 or MOLM-13 xenografts. Clifutinib is promising for research of relapsed/refractory FLT3-ITD-positive acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-144779
CAS No.: 3033417-31-8
Purity:  95.33%
Target:  

HDAC Autophagy

Research Areas:  

Cancer

HDAC10-IN-1 (compound 13b) is a potent and highly selective HDAC10 inhibitor, with an IC50 of 58 nM. HDAC10-IN-1 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .
loading...
    loading...
Cat. No.: HY-144782A
Purity:  ≥95.0%
Target:  

HDAC Autophagy

Research Areas:  

Cancer

HDAC10-IN-2 hydrochloride (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC50 of 20 nM. HDAC10-IN-2 hydrochloride modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .
loading...
    loading...
Cat. No.: HY-143286A
Purity:  99.72%
Target:  

PROTACs FLT3 STAT

Research Areas:  

Cancer

PF15 TFA is an orally active FLT3-ITD PROTAC degrader with a DC50 of 76.7 nM and an IC50 of 36 nM against FLT3-ITD. PF15 TFA induces FLT3-ITD protein degradation, thereby downregulating its phosphorylation level. PF15 TFA inhibits the proliferation of FLT3-ITD-positive cells and reduces the phosphorylation level of STAT5, a downstream molecule of FLT3-ITD. PF15 TFA exhibits efficacy in in vivo xenograft models of acute myeloid leukemia and prolongs survival. PF15 TFA can be used for the research of acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-143286
CAS No.: 2892631-70-6
Target:  

PROTACs FLT3 STAT

Research Areas:  

Cancer

PF15 is an orally active FLT3-ITD PROTAC degrader with a DC50 of 76.7 nM and an IC50 of 36 nM against FLT3-ITD. PF15 induces FLT3-ITD protein degradation, thereby downregulating its phosphorylation level. PF15 inhibits the proliferation of FLT3-ITD-positive cells and reduces the phosphorylation level of STAT5, a downstream molecule of FLT3-ITD. PF15 exhibits efficacy in in vivo xenograft models of acute myeloid leukemia and prolongs survival. PF15 can be used for the research of acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-144782
CAS No.: 3033417-22-7
Target:  

HDAC Autophagy

Research Areas:  

Cancer

HDAC10-IN-2 (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC50 of 20 nM. HDAC10-IN-2 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .
loading...
    loading...
Cat. No.: HY-N10221
CAS No.: 194608-29-2
Petromurin C is a bisindolylbenzenoid compound isolated from the ascostromata of Petromycesmuricatus. Petromurin C induces protective autophagy and apoptosis in FLT3-ITD-positive AML .
loading...
    loading...
Cat. No.: HY-178020
CAS No.: 3020729-11-4
Target:  

FLT3 ERK Akt Apoptosis

Research Areas:  

Cancer

FLT3-IN-34 is a FLT3 inhibitor, with an IC50 value of 1.4 nM. FLT3-IN-34 blocks the phosphorylation of FLT3 and its downstream signaling molecules AKT and ERK1/2. FLT3-IN-34 induces concentration-dependent G0/G1 phase arrest and mild apoptosis in FLT3-ITD-positive MV4-11 cells. FLT3-IN-34 shows potent anti-proliferative activity against FLT3-ITD-positive MV4-11 cells (IC50 = 14.95 nM) and MOLM-13 (IC50 = 18.5 nM). FLT3-IN-34 can be used for the study of FLT3-positive acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-155226
Target:  

FLT3 Apoptosis

Research Areas:  

Cancer

FLT3-IN-21 (compound LC-3) is a potent FLT3 inhibitor (IC50: 8.4 nM) and induces apoptosis. FLT3-IN-21 can arrest the cell cycle in the G1 phase and inhibit the proliferation of FLT3-ITD-positive AML cells MV-4-11 (IC50: 5.3 nM). In mice, FLT3-IN-21 (10 mg/kg/d) inhibited tumor growth in the MV-4-11 xenograft model (TGI=92.16%) .
loading...
    loading...
Cat. No.: HY-155770
Target:  

FLT3

Research Areas:  

Cancer

FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor with IC50 values of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively. FLT3-IN-20 has anti-proliferation efficacy in FLT3-ITD-positive AML cell lines MV4-11 and MOLM-13 (7 and 9 nM, respectively) and the MOLM-13 variant (4 nM) with the FLT3-ITD-D835Y mutation. FLT3-IN-20 can be used in research of cancer .
loading...
    loading...
Cat. No.: HY-182281
Target:  

FLT3 STAT Akt ERK Apoptosis

Research Areas:  

Cancer

FLT3-IN-41 is a highly potent FLT3 inhibitor. The IC50 values of FLT3-IN-41 against human FLT3-ITD and FLT3-WT are 3.16 nM and 294.7 nM, respectively. By binding to the ATP-binding pockets of FLT3-ITD and FLT3-WT and forming hydrogen bonds with hinge region residues and Phe830, FLT3-IN-41 inhibits the STAT5, Akt and Erk signaling pathways. FLT3-IN-41 induces G2/M phase arrest and promotes apoptosis in FLT3-ITD-positive acute myeloid leukemia cells, exhibiting significant antiproliferative activity. FLT3-IN-41 serves as a valuable tool for the study of acute myeloid leukemia .
loading...
    loading...
  • 1